A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
1p/19q deletion by FISH : 1001039
MessagePlease provide most recent Pathology report.
Test Code
MDFCP1P19QFNB or 1001039
Alias/See Also
1p-/19q in Glioma; 1p/19q Deletion Detection; FISH for 1p/19q Deletion in Gliomas ; LOH (Loss of Heterozygosity) 1p/19q in Gliomas; Loss of Heterozygosity (LOH) 1p/19q in Gliomas; Oligodendroglioma
CPT Codes
88271x2, 88274x2
Instructions
Tissue.
Transport Container
Paraffin embedded formalin fixed tissue that has been fixed in 10% neutral buffered formalin for at least 6 hours and no longer than 48 hours. Four unstained slides, with tissue of 4 microns in thickness are needed for processing, accompanied by a circled H & E clearly indicating the area to be examined.
Transport Temperature
Paraffin embedded tissue block: Ambient or on ice pack in summer. Slides: Ambient.
Specimen Stability
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology
Fluorescence in situ hybridization (FISH)
Setup Schedule
Monday - Friday
Report Available
Up to 7 days
Limitations
Laboratory test results should always be considered in the context of clinical observations.. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
Reference Range
An interpretive report will be provided.
Clinical Significance
Anaplastic oligodendrogliomas are characterized by a unique compilation of molecular genetic changes, including coincident loss of chromosomal arms 1p and 19q in 50%-70% of tumors. Allelic loss (or loss of heterozygosity) of chromosome 1p is a statistically significant predictor of chemosensitivity, and combined loss involving chromosomes 1p and 19q is statistically significantly associated with both chemosensitivity and longer recurrence-free survival after chemotherapy.
Performing Laboratory
med fusion